衰弱与身体成分对接受新辅助化疗的上皮性卵巢癌患者术后结局的预测作用
单机构回顾性队列研究纳入179例接受间歇性肿瘤细胞减灭术的上皮性卵巢癌患者,按mFI5分为衰弱组(≥2分,33例,18.4%)与非衰弱组(0-1分,146例,81.5%)。衰弱组合并症更多、体能状态更差,但术后并发症、非居家出院及生存无显著差异;衰弱组CT测量的内脏脂肪面积和皮下脂肪面积更高,骨骼肌指数相似。
要点
- 179例中间型肿瘤细胞减灭术患者中18.4%为衰弱(mFI5≥2分)。
- 衰弱与术后并发症、非居家出院及生存无显著关联。
- 衰弱患者CT内脏脂肪面积和皮下脂肪面积更高,骨骼肌指数相似。
核心结论
- mFI5评估的衰弱在本研究间歇性肿瘤细胞减灭术患者中占18.4%,与术后并发症、非居家出院及生存无显著关联。
- 研究发现衰弱与代谢失调可能存在关联,表现为CT上更高的内脏脂肪面积和皮下脂肪面积。
研究设计与样本
- 单机构回顾性队列研究,纳入接受间歇性肿瘤细胞减灭术的上皮性卵巢癌患者179例。
- 按mFI5将患者分为衰弱组(mFI5≥2分,33例,18.4%)与非衰弱组(mFI5 0-1分,146例,81.5%)。
- 身体成分于治疗前CT扫描上测量,报告为皮下脂肪面积、内脏脂肪面积和骨骼肌指数。
主要发现
- 衰弱组合并症率显著更高、体能状态更低(p<0.001)。
- 两组术后并发症或非居家出院无差异。
- 衰弱组CT上内脏脂肪面积和皮下脂肪面积更高,骨骼肌指数两组相似。
- 衰弱组与非衰弱组无进展生存期和总生存期无统计学显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether the five-factor modified frailty index (mFI5) can predict adverse post-operative outcomes in patients with epithelial ovarian cancer (EOC) undergoing interval cytoreductive surgery (CRS) and if CT-based body composition parameters are correlated with frailty. METHODS: A single-institution, retrospective cohort study of EOC patients undergoing interval CRS was performed. Demographic and clinical data were collected. Body composition was measured on pretreatment CT scans and reported as subcutaneous adipose tissue area (SAT), visceral adipose tissue area (VAT), and skeletal muscle index (SMI). Patients were classified using mFI5 into frail (mFI5 ≥ 2) vs. non-frail (mFI5 0-1) cohorts. Postoperative complications, non-home discharge, body composition parameters, progression-free survival (PFS) and overall survival (OS) were compared between cohorts. RESULTS: Among 179 patients evaluated, 33 patients (18.4 %) were classified as frail, and 146 (81.5 %) were non-frail. Frail patients had significantly higher rates of comorbidities and lower performance status (p < 0.001), but no difference in postoperative complications or non-home discharge was identified. Patients with frailty were more likely to have a higher VAT and SAT area on CT, while SMI was similar among the two cohorts. No statistically significant difference in PFS or OS was observed among frail and non-frail patients. CONCLUSIONS: Frailty as assessed by mFI5 was identified in 18.4 % of patients undergoing interval CRS in our study and was not associated with non-home discharge, postoperative complications or survival. We identified a potential link between frailty and metabolic dysregulation, represented by higher VAT and SAT on CT scans.
引用
- Hansen J, Suratkal J, Shah SN, et al. Frailty and body composition as predictors of postoperative outcomes in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy. Gynecol Oncol. 2025. PMID: 41344123. doi:10.1016/j.ygyno.2025.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。